DMH2  (Synonyms: VU364849)

DMH2 is a potent BMP receptor antagonist. DMH2 downregulates the expression of Id1 and Id3 proteins, and inhibits the proliferation and induces cell death of lung cancer cell lines^[1].

DMH2 decreases expression of Id1 and Id3 and causes growth suppression of three lung cancer cell lines with K-Ras mutation (A549, H157, H727) and three without a K-Ras mutation (H1299, H865, U1752)^[1].
The combination of DMH2 and PP2 causes significantly greater reduction in Id1 promoter activity and growth inhibition than either agent alone in the A549 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

DMH2 (0-2 mg/kg, IP, twice daily, for 2 days prior to PH (partial hepatectomy) and for 2 days after PH) increases hepatocyte proliferation from 13.7% to 26.9% at 2 mg/kg^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

451.52

C₂₇H₂₅N₅O₂

1206711-14-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Langenfeld J E, Langenfeld E. Src inhibition enhances BMP receptor antagonists downregulation of Id1 and growth suppression of lung cancer cells with a K-Ras mutation. 2013:5263.

  [2]. Tsugawa D, Oya Y, Masuzaki R, et al. Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. J Pharmacol Exp Ther. 2014;351(3):549-558.  [Content Brief]